Kestra Private Wealth Services LLC Has $2.18 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Kestra Private Wealth Services LLC lowered its stake in Cencora, Inc. (NYSE:COR - Free Report) by 33.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,692 shares of the company's stock after selling 4,827 shares during the period. Kestra Private Wealth Services LLC's holdings in Cencora were worth $2,178,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Cencora by 3.8% in the third quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after buying an additional 291,867 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after buying an additional 338,452 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cencora by 4.7% in the third quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company's stock valued at $941,183,000 after buying an additional 189,054 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of Cencora by 6.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock valued at $495,249,000 after buying an additional 138,868 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Cencora by 21.7% in the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after buying an additional 292,600 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on COR. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Barclays lifted their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird lifted their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average price target of $277.90.

Cencora Stock Down 0.6 %

Shares of Cencora stock traded down $1.50 on Friday, hitting $243.03. 1,277,896 shares of the company traded hands, compared to its average volume of 1,327,143. The company has a 50-day moving average price of $238.70 and a 200 day moving average price of $237.42. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The company has a market cap of $46.97 billion, a PE ratio of 34.57, a PEG ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,187 shares of company stock worth $17,790,912. Corporate insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.